Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Effect of long-acting injectable paliperidone 3 monthly and aripiprazol 1 monthly on hospitalization rate in a first-episode psychosis

  • P. Gil Lopez, J.M. Rodriguez Sanchez, L. Garcia Fernandez, V. Sanchez Estevez
  • Journal:
    European Psychiatry / Volume 64 / Issue S1 / April 2021
    Published online by Cambridge University Press:
    13 August 2021, p. S812
    • Article
      • You have access
      • Open access
    • PDF
    • Export citation
  • Introduction

    Long-acting injectable antipsychotics (LAIs) can reduce relapse and hospitalization risk but they are not widely used in first psychotic episode (FEP) patientes.

    Objectives

    To examine the effcacy of two of the most used second generation LAI antipsychotics (paliperione 3 monthly and aripiprazol 1 monthly) to reduce hospitalization rates.

    Methods

    We evaluated in a naturalistic study a sample of patients (n=277) with a FEP. We carried out a mirror-design study to compare the number of hospitalizations and days in hospital before and after the introduction of LAI paliperidone (3 monthly) or LAI aripiprazol. In our Early Intervention Services (Lehenak) antipsychotic treatment is not protocolized and is established for each patient according to the psychiatrist criteria.

    Results

    We review the oucome of 277 FEP treated in our Early Intervention Service “Lehenak” with LAI paliperidone 3 monthly (n=156) or LAI Aripiprazol (n=121)

    Pre LAI Mirror PeriodPost LAI Mirror PeriodWithin group comparisons (paired t-test) t p
    Aripiprazol LAI number of Hospitalizations (mean, standard deviation)2.31 (1.72)0.73 (1.23)17.4 (<0.001)
    Paliperidone LAI 3 monthly number of Hospitalizations number0,68 (0.93)0.15 (0.47)4.62 (<0.001)
    Aripiprazol LAI Days in Hospital30.26 (33.52)17.02 (38.19)2.93 (0.004)
    Paliperidone LAI 3 monthly Days in hospital12.63 (24.23)3.40 (14.18))7.5 (<0.001)

    Conclusions

    Both LAI paliperidone 3 monthly and LAI aripiprazol had a postive impact on hospitalIzation rate, decreasing them significantly after their introduction. These data also support a more extensive use of LAI paliperidone 3 monthly in FEP.

    Disclosure

    Presenting author has received honouraria for lectures or advisory boards from Janssen, Otsuka, Lundbeck and Angelini in the last five years